Magenta Therapeutics, Inc.

Jason Gardner is just a month into his role as CEO of Ampersand Biomedicines , one of the latest companies to emerge from Flagship Pioneering , but is nevertheless confident it can deliver a “new pa

After a month and a half initial public offering drought, two biopharmaceutical companies – Neumora Therapeutics, Inc. and RayzeBio, Inc. – launched IPOs in the US and grossed $561m combined on 14

Gamida Cell Ltd. ’s Omisirge (omidubicel-onlv) will be the first substantially modified cord blood-based stem cell graft source for allogeneic hematopoietic progenitor cell transplantation following F

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Newly Public Dianthus Projects Financia